Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 18 years of age or older.~2. Moderate to severe LCL at maximum smile as assessed by the Investigator.~3. Moderate to severe LCL at maximum smile as assessed by the subject.~4. Moderate to severe GL at maximum frown as assessed by the Investigator.~5. Moderate to severe GL at maximum frown as assessed by the subject~Exclusion Criteria:~1. Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment.~2. Female who is pregnant, breast feeding, or intends to conceive a child during the study.~3. Known allergy or hypersensitivity to any component of the investigational product (QM1114-DP).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- QM1114-DP in the LCL + Placebo in the GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection
- Placebo in the LCL and GL (Type: PLACEBO_COMPARATOR): A buffered solution; Mode of administration:~intramuscular injection
- Placebo in the LCL + QM1114-DP in the GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) or placebo Mode of administration: intramuscular injection
- QM1114-DP in the LCL + GL (Type: EXPERIMENTAL): QM1114-DP, a Botulinum Toxin Type A (BoNT-A) ; Mode of administration: intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).